May 17, 2020

Renal Denervation Trials Tirelessly Try to Improve Cardiac Health

Admin
4 min
Renal Denervation Trials Tirelessly Try to Improve Cardiac Health.jpg
Written by Alyssa Clark As the success of the recent renal denervation trials goes up, patients blood pressure continues to go down— as much as...

Written by Alyssa Clark

 

As the success of the recent renal denervation trials goes up, patients’ blood pressure continues to go down— as much as 30 mm Hg down. This recently implemented catheter-based blood pressure lowering technology has consistently generated results that directly correlate with patients’ increase in heart health and longevity.

Eliminating the complications of relying on drug therapy for patients, this renal deneration is working its way up to being called the “cure” for resistant hypertension, Medical device companies and the cardiac community alike are both equally excited about the possibilities that come with this new wave of cardiac-health solutions, and the profitability of this technology as it continues to grow. The ability for this technology to be expanded into more moderate forms of hypertension and other disease is now actively being pursued by researches.

However, the most recent tests of this technology have produced much more realistic results changing that 30mm Hg reduction to a much more reasonable 11 mm Hg reduction.

Hypertension experts Franz Messerli and Sripal Bangalore agree that the hype over renal denervation is due for deflation, “Small wonder that the cookie is finally crumbling, bigger wonder that it actually took so long. The irrational exuberance for renal denervation in resistant hypertension was entirely driven by uncontrolled non-randomized observational office-based blood pressure studies. We showed that in the Spanish registry of more than 8000 patients about a quarter of patients with office blood pressures of above 160/100 were actually normotensive when monitored by 24-hour ambulatory blood pressure(ABPM ). Further, in this same Spanish registry about one third of patients with resistant hypertension based on office blood pressure measurements had normotensive ABPMs. Thus many patients with so-called resistant hypertension by office blood pressure measurements may be pseudo-resistant only. This would indicate that the exaggerated benefits observed with office blood pressure measurements are due to the simple fact that some patients actually had normal blood pressure at trial baseline. Conceivably many of these patients have white coat hypertension which is unmasked by ABPM”.

The senior author of the most recent paper about this change in reduction prediction is a man named Darrel Francis, he says “that the real effect of a 10-15 mm Hg drop in pressure ‘is very worthwhile, but talking about 2 or 3 times that effect size does nobody any good, because it eliminates the scope for scientific discussion’”.

Rest assured though that there is light at the end of the tunnel, and that this gap isn't truly as negative as it may be perceived. Wendy Dougherty, Director of Public Relations from Medtronic explains the disjunction in these numbers as: "There are many reasons why these two measures would be different. The reason for the lower ABPM is expected  as BP is lower at night, so average BP will be less and the multiple readings give a different outcome (averaged SBP over 24 hours) rather that obtained by a single reading. Comparing Office Blood Pressure Monitoring and ABPM is an apples to oranges comparison - they report on different measurements and would not be expected to be the same. Also lost is the observation of a very consistent drop by ABPM that is being observed (~11 mm Hg) in the limited but growing RDN ABPM data that is available and that this is a very significant effect that should have very important and substantial clinical benefit".

Renal Denervation is a valuable tool, but is not approved by the FDA to be used in the U.S., with products available in Europe from Medtronic, St. Jude Medical, Boston Scientific, Coviden, Recor and Terumo. As stated earlier, tons of medical device companies are chomping at the bit to get in on the action concerning this new technology, it just seems to be some medical professionals are losing their heads about the realistic expectations of this technology; if we stay grounded in terms of our expectations and goals for this technology it can help the world in new and expanding ways.

 

About the Author

Alyssa Clark is the Editor of Healthcare Global

Share article

Jun 22, 2021

NeuTigers: edge AI in healthcare

edgecomputing
edgeAI
AI
prediction
3 min
We take a look at edge AI and how NeuTigers is driving this forward in healthcare

What is edge AI? 

Edge AI is essentially a combination of edge computing and artificial intelligence. Algorithms are processed locally - directly on a mobile device or server - rather than in the cloud. This reduces cost, computing power and energy requirements. There are also claims that edge AI is so fast it is possible to reach near real-time analytics

Edge AI devices include smart speakers, smart phones, laptops, robots, self-driven cars, drones, and surveillance cameras that use video analytics. 

Who is NeuTigers? 

NeuTigers is a spin-off company from Princeton University, formed in 2018 to apply edge AI and machine learning to solve challenges in healthcare, energy, productivity, and security. 

With offices in Princeton, NJ, the company is based at one of the top AI accelerator programs of FutureLabs in New York, and has also established a subsidiary in Nice, France.

How is NeuTigers applying edge AI to healthcare? 

The NeuTigers AI Technology Stack uses deep  neural networks that mimic how the human brain perceives and interprets the world. The company has developed the StarDeepTM Smart Health Platform for health monitoring and biomedical imaging, to improve the accuracy and speed of diagnosing diseases. 

NeuTigers say the platform has the potential to monitor and screen for thousands of conditions,  when used in combination with medical devices and  smart sensors already deployed in healthcare settings. 

Are there any real world examples? 

In January NeuTigers launched CovidDeep, a tool that predicts COVID-19 with more than 90% accuracy, using physiological data from a wristband along with blood pressure and blood oxygen readings. It then analyses the data and gives a prediction within two minutes. 

This week NeuTigers announced a new study to detect the early signs of  complications with sickle cell anaemia.  Conducted at a hospital in Paris, the research will begin by looking at changes to skin response, heart beat, sleep and temperature to predict an acute episode of sickle cell anaemia, and how this impacts on the patients’ disease conditions and quality of life. 

The second phase of the project is to expand with prospective studies across different sites in EU, Africa  and the US to explore the models' accuracy and clinical effectiveness. 

They say...

Adel Laoui, CEO and founder of NeuTigers, says: “The best way to deal with a crisis is to avoid it happening in the first place. We are now entering a new era where medical early warning systems have become a reality. 

“We are excited at the possibility of deploying a technology that can save lives of patients dealing with sickle cell anaemia. The potential of the StarDeep platform to dramatically improve patient outcomes while slashing some of the highest costs of healthcare makes it one of the most exciting developments in preventative personal medicine.”

Share article